FDA GRAS Notice 947: What It Means for the Cacao Industry

The Regulatory Milestone That Changed Everything

On September 28, 2020, the FDA issued its "no questions" letter for GRAS Notice 947, marking a pivotal moment for the cacao industry. This wasn't just another regulatory filing—it was the first comprehensive safety determination for cacao mucilage products in the United States, backed by 144 pages of scientific evidence and opening a multi-billion dollar market opportunity.

Understanding GRAS: More Than Just Approval

What GRAS Actually Means

Generally Recognized As Safe (GRAS) is a rigorous FDA designation that requires:

• Scientific consensus among qualified experts
• Publicly available safety data
• Common knowledge throughout the scientific community
• Reasonable certainty of no harm under intended use Unlike food additives that require pre-market FDA approval, GRAS substances can enter the market immediately—but the evidence standard is equally stringent.

The High Bar for GRAS Status

Only 35% of GRAS notifications receive "no questions" letters¹. The FDA can respond with:

• ✅ "No questions" - Full acceptance (GRN-947 achieved this)
• ⚠️ "Questions remain" - Additional data needed
• ❌ "Notice withdrawn" - Insufficient evidence

Inside GRN-947: The Evidence Package

Who Filed and Why It Matters

Notifier: CABOSSE Naturals NV (Barry Callebaut subsidiary)

• World's largest chocolate manufacturer
• $7.2 billion annual revenue
• 60+ years of cacao expertise
• Resources for comprehensive safety testing This isn't a startup making claims—it's the industry leader investing in mucilage valorization.

The Comprehensive Safety Assessment

The 144-page dossier included²: 1. Compositional Analysis

• Macronutrients (proteins, carbohydrates, fats)
• Micronutrients (vitamins, minerals)
• Bioactive compounds (polyphenols, methylxanthines)
• Potential contaminants (heavy metals, mycotoxins)
• Comparison with 200+ food products 2. Toxicological Evaluation Acute toxicity: No adverse effects at 5g/kg body weight Subchronic (90-day): NOAEL >1000 mg/kg/day Genotoxicity: Negative in Ames test Allergenicity: No cross-reactivity detected Special populations: Safe for children, elderly 3. Consumption Modeling Using NHANES data (2013-2016), the FDA evaluated:
• Average intake: 12.8g/person/day
• 90th percentile: 29.4g/person/day
• Heavy consumers: 47.3g/person/day
• All levels: Well below safety thresholds 4. Manufacturing Standards
• HACCP protocols required
• Microbiological specifications defined
• Heavy metal limits established
• Pesticide residue monitoring
• Shelf stability validated

Approved Uses and Maximum Levels

Food Category Authorizations

| Category | Maximum Use Level | Example Applications | | | Beverages | 20% by weight | Juices, smoothies, functional drinks | | Bakery Products | 15-65% | Muffins, breads, cookies | | Confections | 30% | Non-chocolate candies, gummies | | Dairy Products | 40% | Yogurts, ice cream, cheese | | Cereal Products | 25% | Granola bars, breakfast cereals | | Fruit Preparations | 50% | Jams, jellies, fruit spreads | | Nutrition Bars | 35% | Protein bars, meal replacements |

What This Means for Innovation

These broad categories enable:

• Immediate market entry without further approval
• Product diversification across segments
• Co-branding opportunities with established products
• Premium positioning with regulatory backing

Safety Parameters Established

Methylxanthine Safety Profile

The FDA specifically evaluated theobromine and caffeine³: Theobromine Analysis:

• Content: 2.66 mg/100ml in juice
• Daily intake at 90th percentile: 0.78 mg/kg body weight
• Safety threshold: 30 mg/kg body weight
• Safety margin: 38-fold Comparative Context:
• Dark chocolate (70%): 800 mg/100g theobromine
• Milk chocolate: 200 mg/100g theobromine
• Cacao mucilage: 2.66 mg/100ml
• Conclusion: Negligible methylxanthine exposure

Microbiological Standards

GRN-947 established specifications:

• Total plate count: <1,000 CFU/g
• Yeast and mold: <100 CFU/g
• E. coli: Negative/25g
• Salmonella: Negative/25g
• Listeria: Negative/25g

Heavy Metal Limits

Maximum allowable levels:

• Lead: <0.1 ppm
• Cadmium: <0.1 ppm
• Mercury: <0.01 ppm
• Arsenic: <0.1 ppm
• All below FDA action levels

Global Regulatory Alignment

International Recognition Following FDA

The FDA's acceptance triggered global regulatory momentum: European Union (2021):

• Traditional food status granted
• No novel food application required
• Full market access in 27 countries Health Canada (2021):
• Natural health product approved
• Functional claims permitted
• No temporary marketing authorization needed Australia/New Zealand (2022):
• Non-novel food determination
• FSANZ positive assessment
• Immediate market entry allowed Japan (2023):
• Foods for Specified Health Uses (FOSHU) eligible
• Functional labeling permitted
• No additional safety assessment required

Commercial Implications

For Manufacturers

Reduced Barriers:

• No additional FDA filing needed
• Reference GRN-947 in formulations
• Established safety parameters
• Clear labeling guidelines Risk Mitigation:
• Liability protection through FDA review
• Insurance coverage easier to obtain
• Investor confidence increased
• Supply chain acceptance accelerated

For Brand Owners

Marketing Advantages:

• "FDA GRAS" on labels
• Safety story for consumers
• Premium positioning justified
• Clean label achievement Innovation Opportunities:
• Functional beverage development
• Sports nutrition applications
• Children's products possible
• Medical food potential

For Distributors

Market Access:

• All 50 U.S. states
• No special permits required
• Retail chains acceptance
• E-commerce approved Due Diligence Simplified:
• Regulatory compliance confirmed
• Safety documentation available
• Quality standards established
• Traceability requirements defined

Competitive Landscape Impact

Market Dynamics Shift

Before GRN-947:

• Limited to dietary supplements
• Regulatory uncertainty
• Restricted claims
• Niche market only After GRN-947:
• Mainstream food ingredient
• Clear regulatory pathway
• Structure/function claims allowed
• Mass market potential

First-Mover Advantages

Companies leveraging GRN-947:

• 6-12 month head start on competitors
• Premium pricing (40-60% above alternatives)
• Exclusive partnerships with major brands
• Category leadership positioning

Practical Application Guide

How to Reference GRN-947

For Product Development:

1. Review maximum use levels for your category
2. Ensure processing meets specifications
3. Implement required quality controls
4. Maintain documentation for audits For Regulatory Filings:

• Reference: "FDA GRAS Notice GRN No. 947"
• Citation: "Cacao pulp, juice, and concentrate"
• Notifier: "CABOSSE Naturals NV"
• Date: "September 28, 2020" For Marketing Materials: Acceptable claims:
• "Made with FDA GRAS ingredients"
• "Cacao mucilage (FDA GRAS No. 947)"
• "Safety reviewed by FDA" Avoid claiming:
• "FDA approved" (GRAS ≠ approval)
• "FDA endorsed" (misrepresentation)
• Medical or disease claims

Investment and M&A Implications

Valuation Impact

Companies with GRAS ingredients command:

• 2.5-3.5x higher revenue multiples
• Lower risk profile for investors
• Faster due diligence processes
• Better financing terms

Strategic Value

GRN-947 creates:

• Acquisition targets for major food companies
• Partnership opportunities with CPG brands
• Licensing potential for technology
• International expansion platforms

Future Regulatory Landscape

Upcoming Developments

Health Claims Petition (Expected 2025):

• Cardiovascular health claims
• Antioxidant content claims
• Natural electrolyte claims Organic Certification (In Progress):
• USDA Organic compatibility
• EU Organic standards
• Processing aid classification Codex Alimentarius (2024-2026):
• International standard development
• Global trade facilitation
• Harmonized specifications

Critical Success Factors

For New Entrants

Must-Haves:

1. Processing alignment with GRN-947
2. Quality systems implementation
3. Traceability documentation
4. Scientific substantiation
5. Legal review of claims Nice-to-Haves:

• Third-party certification
• Additional safety studies
• Sustainability verification
• Clinical trials for differentiation

The Bottom Line

FDA GRAS Notice 947 transforms cacao mucilage from agricultural waste to validated food ingredient. This regulatory milestone: ✅ Eliminates market entry barriers ✅ Validates safety across populations
✅ Enables immediate commercialization ✅ Supports premium positioning ✅ Facilitates global expansion For companies in the cacao value chain, GRN-947 isn't just regulatory compliance—it's a competitive advantage worth millions.

References

¹ FDA (2023). "GRAS Notice Inventory Statistics." FDA.gov/food/gras-notice-inventory ² FDA GRAS Notice GRN-947 (2020). "CABOSSE Naturals NV Cacao Pulp, Juice and Concentrate." Available at: FDA.gov/media/143571/download ³ JECFA (1996). "Toxicological evaluation of certain food additives: Theobromine." WHO Technical Report Series No. 35. For technical specifications and implementation guidance, consult our research library or review safety parameters for detailed information.

Learn More About Cacao Mucilage

• Complete Nutritional Profile - Discover the antioxidants and compounds
• Science-Backed Health Benefits - Research on cardiovascular and cognitive effects
• Sustainability Impact - How mucilage reduces waste and increases farmer income
• Commercial Applications - How the industry uses cacao mucilage